New Antibody-Based Approach Enables Safer Stem Cell Transplantation for Fanconi Anemia
A phase 1b trial shows that an anti-CD117 antibody (briquilimab) enables stem cell transplantation without toxic irradiation or busulfan in children with Fanconi anemia.